Quest AD-Detect p-tau217/Beta-Amyloid 42 Ratio, Plasma

Quest AD-Detect p-tau217/Beta-Amyloid 42 Ratio, Plasma3 biomarkers

Overview:

p-tau217 (ratio component)

This p-tau217 value is used to calculate the p-tau217/beta-amyloid 42 ratio. Quest provides interpretation for the ratio.

Beta-Amyloid 42 (Aβ42), Plasma

Beta-amyloid 1-42 (Aβ42) is the amyloid peptide that aggregates into the plaques characteristic of Alzheimer's disease. As plaques accumulate in the brain, the amount of Aβ42 circulating in blood tends to fall. Plasma Aβ42 is interpreted together with p-tau217 through the p-tau217/beta-amyloid 42 ratio rather than as a standalone value.

p-tau217/Beta-Amyloid 42 Ratio, Plasma

The plasma p-tau217/beta-amyloid 42 ratio (Fujirebio Lumipulse G) is FDA cleared to help assess the presence or absence of amyloid plaques in adults aged 50 and older who show signs or symptoms of cognitive decline. A lower ratio makes amyloid pathology less likely; a higher ratio makes it more likely and typically warrants confirmatory evaluation (amyloid PET or CSF testing). It is an aid to diagnosis, not a standalone diagnosis, and has not been validated for screening people without symptoms.

Quest test code: 17970
1 test, 3 biomarkers

Categories

Stress & Aging

$945